ECSP15017314A - Formulacion de anticuerpos - Google Patents
Formulacion de anticuerposInfo
- Publication number
- ECSP15017314A ECSP15017314A ECIEPI201517314A ECPI201517314A ECSP15017314A EC SP15017314 A ECSP15017314 A EC SP15017314A EC IEPI201517314 A ECIEPI201517314 A EC IEPI201517314A EC PI201517314 A ECPI201517314 A EC PI201517314A EC SP15017314 A ECSP15017314 A EC SP15017314A
- Authority
- EC
- Ecuador
- Prior art keywords
- cells
- baffr
- antibody
- survival
- baff
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El par BAFFR:BAFF está profundamente involucrado en la maduración de las células B de transición, para la supervivencia y la activación de las células B maduras, y para la conmutación de clase de isotipo en respuesta a antígenos dependientes de células T. BAFF y su receptor BAFFR también son importantes para la supervivencia y el crecimiento de células B malignas. Además, BAFFR normalmente no se expresa en células pre-B, pero 10 recientemente se mostró expresado en células humana de ALL (leucemia linfoblástica aguda de linaje B) (Parameswaran, 2010, Cancer Res. 70(11) 4346-4356). La eliminación de las células B auto-reactivas y el bloqueo de supervivencia/activación no apropiadas mediadas por los niveles BAFF de exceso en pacientes que sufren de trastornos autoinmunes o cáncer representa un objetivo terapéutico bien validado. Por lo tanto, un anticuerpo anti-BAFFR, en 15 particular, un anticuerpo capaz de citotoxicidad mediada por células dependiente de anticuerpos (ADCC) y el bloqueo de la unión del ligando a BAFFR puede constituir un agente terapéutico eficaz en las enfermedades autoinmunes y neoplasias de células B. Los anticuerpos contra BAFFR se conocen a partir de, por ejemplo, el documento WO 2010/007082 e incluyen anticuerpos que se caracterizan por que comprenden un dominio VH 20 con la secuencia de aminoácidos de la SEC ID No: 1 y un dominio VL con la secuencia de aminoácidos de SEQ ID NO: 2. El anticuerpo MOR6654 es uno de estos anticuerpos (IgG1 kappa). Éste tiene
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658472P | 2012-06-12 | 2012-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15017314A true ECSP15017314A (es) | 2018-06-30 |
Family
ID=48914378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201517314A ECSP15017314A (es) | 2012-06-12 | 2015-01-12 | Formulacion de anticuerpos |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9216219B2 (es) |
| EP (2) | EP2858671B1 (es) |
| JP (1) | JP6265978B2 (es) |
| KR (1) | KR102124820B1 (es) |
| CN (1) | CN104363920B (es) |
| AR (1) | AR091413A1 (es) |
| AU (1) | AU2013276112B2 (es) |
| BR (1) | BR112014030820B1 (es) |
| CA (1) | CA2875386C (es) |
| CL (1) | CL2014003370A1 (es) |
| CO (1) | CO7151487A2 (es) |
| CY (1) | CY1122181T1 (es) |
| DK (1) | DK2858671T3 (es) |
| EA (1) | EA033373B1 (es) |
| EC (1) | ECSP15017314A (es) |
| ES (1) | ES2751659T3 (es) |
| GT (1) | GT201400285A (es) |
| HK (1) | HK1203146A1 (es) |
| HR (1) | HRP20191827T1 (es) |
| HU (1) | HUE045523T2 (es) |
| IL (1) | IL235966B (es) |
| LT (1) | LT2858671T (es) |
| MA (1) | MA37616A1 (es) |
| MX (1) | MX363380B (es) |
| MY (1) | MY179818A (es) |
| NZ (1) | NZ630885A (es) |
| PE (1) | PE20150200A1 (es) |
| PH (1) | PH12014502778A1 (es) |
| PL (1) | PL2858671T3 (es) |
| PT (1) | PT2858671T (es) |
| SG (1) | SG11201408174UA (es) |
| SI (1) | SI2858671T1 (es) |
| TN (1) | TN2014000488A1 (es) |
| TW (1) | TWI653983B (es) |
| WO (1) | WO2013186700A1 (es) |
| ZA (1) | ZA201408547B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3459564T (pt) | 2010-01-06 | 2022-01-31 | Takeda Pharmaceuticals Co | Proteínas de ligação à calicreína plasmática |
| US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| KR102107695B1 (ko) | 2011-01-06 | 2020-05-07 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| TW201922795A (zh) | 2012-09-10 | 2019-06-16 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CN104730237A (zh) * | 2013-12-23 | 2015-06-24 | 国家纳米科学中心 | 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法 |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| US10407506B2 (en) | 2014-03-12 | 2019-09-10 | Prothena Biosciences Limited | Anti-MCAM antibodies and associated methods of use |
| KR101597037B1 (ko) | 2014-06-26 | 2016-02-24 | 엘지디스플레이 주식회사 | 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3286226A4 (en) * | 2015-03-30 | 2018-12-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| DK3386541T3 (da) * | 2015-12-07 | 2020-09-28 | Merck Patent Gmbh | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
| US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| TWI836745B (zh) * | 2015-12-18 | 2024-03-21 | 美商上游生物公司 | 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物 |
| MA45381A (fr) * | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
| US20180118811A1 (en) | 2016-10-19 | 2018-05-03 | Invenra Inc. | Antibody constructs |
| CN110291107B (zh) | 2016-12-22 | 2023-05-05 | 卡坦扎罗麦格纳格拉西亚大学 | 靶向cd43的独特唾液酸糖基化的癌症相关表位的单克隆抗体 |
| CA3235178A1 (en) * | 2017-03-01 | 2018-09-07 | Medimmmune Limited | Formulations of monoclonal antibodies |
| US11639391B2 (en) * | 2017-04-18 | 2023-05-02 | Dr. Reddy's Laboratories Limited | Stable liquid pharmaceutical composition |
| DK3658184T3 (da) | 2017-07-27 | 2023-11-27 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| AU2018321335A1 (en) * | 2017-08-22 | 2020-02-27 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| CA3083356A1 (en) * | 2017-11-29 | 2019-06-06 | Prothena Biosciences Limited | Lyophilized formulation of a monoclonal antibody against transthyretin |
| SG11202011984UA (en) | 2018-06-05 | 2020-12-30 | King S College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| EP3897714A1 (en) * | 2018-12-18 | 2021-10-27 | Novartis AG | Protein solution formulation containing high concentration of an anti-vegf antibody |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| TWI764097B (zh) * | 2019-02-26 | 2022-05-11 | 大陸商信達生物製藥（蘇州）有限公司 | 包含抗ｃｄ４７抗體的製劑及其製備方法和用途 |
| CA3160207A1 (en) | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjogren's syndrome |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| EP4094777A4 (en) * | 2020-01-21 | 2024-01-24 | Innovent Biologics (Suzhou) Co., Ltd. | RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| IL300086A (en) | 2020-08-04 | 2023-03-01 | Novartis Ag | Treatment of B-cell malignancies |
| CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
| JP2024517796A (ja) | 2021-05-04 | 2024-04-23 | ノバルティス アーゲー | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 |
| CA3215919A1 (en) | 2021-05-04 | 2022-11-10 | Novartis Ag | Treatment for systemic lupus erythematosus using anti-baffr antibodies |
| AU2022354054A1 (en) * | 2021-09-29 | 2024-03-28 | Dragonfly Therapeutics, Inc. | Antibodies targeting baff-r and use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP1192243A4 (en) | 1999-06-23 | 2003-05-28 | Univ Oregon Health & Science | METHOD FOR REINFORCING HEMATOPOIESE |
| CA2412701A1 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
| DK1441589T3 (da) | 2001-11-08 | 2012-08-06 | Abbott Biotherapeutics Corp | Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer |
| EP1946776B1 (en) | 2002-02-27 | 2017-01-18 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EA200701211A1 (ru) * | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
| US8106163B2 (en) | 2008-07-17 | 2012-01-31 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
| BR112012011539A8 (pt) * | 2009-11-17 | 2017-12-26 | Ipsen Pharma Sas | formulação para a combinação de hgh e rhigf-1 |
| US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
-
2013
- 2013-06-07 US US13/912,355 patent/US9216219B2/en active Active
- 2013-06-10 MA MA37616A patent/MA37616A1/fr unknown
- 2013-06-11 SI SI201331596T patent/SI2858671T1/sl unknown
- 2013-06-11 HU HUE13744818A patent/HUE045523T2/hu unknown
- 2013-06-11 DK DK13744818.9T patent/DK2858671T3/da active
- 2013-06-11 EP EP13744818.9A patent/EP2858671B1/en active Active
- 2013-06-11 BR BR112014030820-9A patent/BR112014030820B1/pt active IP Right Grant
- 2013-06-11 PL PL13744818T patent/PL2858671T3/pl unknown
- 2013-06-11 MX MX2014015262A patent/MX363380B/es unknown
- 2013-06-11 EA EA201492292A patent/EA033373B1/ru not_active IP Right Cessation
- 2013-06-11 KR KR1020157000336A patent/KR102124820B1/ko active IP Right Grant
- 2013-06-11 SG SG11201408174UA patent/SG11201408174UA/en unknown
- 2013-06-11 LT LT13744818T patent/LT2858671T/lt unknown
- 2013-06-11 AU AU2013276112A patent/AU2013276112B2/en active Active
- 2013-06-11 JP JP2015516723A patent/JP6265978B2/ja active Active
- 2013-06-11 NZ NZ630885A patent/NZ630885A/en not_active IP Right Cessation
- 2013-06-11 WO PCT/IB2013/054777 patent/WO2013186700A1/en active Application Filing
- 2013-06-11 ES ES13744818T patent/ES2751659T3/es active Active
- 2013-06-11 CN CN201380031181.8A patent/CN104363920B/zh active Active
- 2013-06-11 MY MYPI2014703690A patent/MY179818A/en unknown
- 2013-06-11 PT PT137448189T patent/PT2858671T/pt unknown
- 2013-06-11 CA CA2875386A patent/CA2875386C/en active Active
- 2013-06-11 TW TW102120795A patent/TWI653983B/zh active
- 2013-06-11 EP EP19185836.4A patent/EP3593814A1/en active Pending
- 2013-06-11 PE PE2014002437A patent/PE20150200A1/es not_active Application Discontinuation
- 2013-06-12 AR ARP130102057 patent/AR091413A1/es not_active Application Discontinuation
-
2014
- 2014-11-20 ZA ZA2014/08547A patent/ZA201408547B/en unknown
- 2014-11-21 TN TN2014000488A patent/TN2014000488A1/fr unknown
- 2014-11-27 IL IL235966A patent/IL235966B/en active IP Right Grant
- 2014-12-11 PH PH12014502778A patent/PH12014502778A1/en unknown
- 2014-12-11 CL CL2014003370A patent/CL2014003370A1/es unknown
- 2014-12-11 GT GT201400285A patent/GT201400285A/es unknown
- 2014-12-18 CO CO14278419A patent/CO7151487A2/es unknown
-
2015
- 2015-01-12 EC ECIEPI201517314A patent/ECSP15017314A/es unknown
- 2015-04-15 HK HK15103657.1A patent/HK1203146A1/xx unknown
- 2015-11-16 US US14/942,388 patent/US9751951B2/en active Active
-
2017
- 2017-08-31 US US15/692,490 patent/US20180051092A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,411 patent/US10689451B2/en active Active
-
2019
- 2019-10-09 HR HRP20191827TT patent/HRP20191827T1/hr unknown
- 2019-10-22 CY CY20191101096T patent/CY1122181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15017314A (es) | Formulacion de anticuerpos | |
| JP2017528462A5 (es) | ||
| CY1123739T1 (el) | Αντισωματα anti-cd38 | |
| TN2016000142A1 (en) | Specific anti-cd38 antibodies for treating human cancers. | |
| EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
| ECSP20020111A (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
| PH12020552080A1 (en) | Dll3-cd3 bispecific antibodies | |
| RU2014147741A (ru) | Модифицированные области антител и их применение | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| EA201691747A1 (ru) | Варианты комбинированной терапии с антителами анти-cd38 | |
| JP2017507954A5 (es) | ||
| PH12015501493B1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| SG10201804945WA (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| AU2011262758A8 (en) | Anti-tim-3 antibody | |
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| UA94452C2 (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
| PH12021550764A1 (en) | Trem2 stabilizing antibodies | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| MX2021004732A (es) | Anticuerpos de cadena pesada que se unen a cd38. | |
| RU2016121105A (ru) | Антитело к gd2-o-ацетилированному ганглиозиду с проапоптозной активностью | |
| MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. |